To study selective reporting in clinical study reports, company trial registers and publications of quality of life in placebo-controlled trials of antidepressants.
METHODS:
We compared clinical study reports of four antidepressants (fluoxetine, duloxetine, paroxetine and sertraline) obtained from two European drug regulators, data from online company registers, and publications received or retrieved from Eli Lilly and GlaxoSmithKline. Pfizer was also contacted but did not provide any publications.
RESULTS:
We included 15 trials (19,015 pages) and 4717 patients. Six trials had used SF-36, seven EQ-5D and two both instruments. Nine of the 15 CSRs (60%) displayed selective reporting. In the companies’ online registers, there was selective reporting for all 15 trials (100%). We received 20 publications from Eli Lilly and retrieved six from the GlaxoSmithKline register. There was selective reporting in 24 of the 26 publications (92%). Despite extensive selective reporting, we found only small differences between placebo and active drugs.
CONCLUSIONS:
Access to the full raw data from clinical trials and to case report forms for all patients are needed to evaluate the effect of antidepressants on quality of life. Regulatory agencies should refuse to approve drugs or new indications based on incomplete reporting.
ChanAWHróbjartssonAHaahrMTGøtzschePCAltmanDG. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA. 2004;291:2457–65.
2.
DickersinKChanSChalmersTCSacksHSSmithJ. Publication bias and clinical trials. Control Clin Trials. 1987;8:343–53.
3.
RossJSMulveyGKHinesEMNissenSEKrumholzHM. Trial publication after registration in clinicaltrials.gov: A cross-sectional analysis. PLoS Med. 2009;6:e1000144.
4.
SchererRWLangenbergPvon ElmE. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007;2:MR000005.
5.
SongFParekhSHooperLLokeYKRyderJSuttonAJDissemination and publication of research findings: An updated review of related biases. Health Technol Assess. 2010;14:1–93.
6.
DoshiPDickersinKHealyDVedulaSSJeffersonT. Restoring invisible and abandoned trials: A call for people to publish the findings. BMJ. 2013;346:f2865.
7.
SharmaTGuskiLSFreundNGøtzschePC. Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports. BMJ. 2016;352:i65.
8.
TurnerEHMatthewsAMLinardatosETellRARosenthalR. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.
9.
WhittingtonCJKendallTFonagyPCottrellDCotgroveABoddingtonE. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet. 2004;363:1341–5.
10.
Le NouryJNardoJMHealyDJureidiniJRavenMTufanaruCRestoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015;351:h4320.
11.
WieselerBWolframNMcGauranNKerekesMFVervoelgyiVKohleppPCompleteness of reporting of patient-relevant clinical trial outcomes: Comparison of unpublished clinical study reports with publicly available data. PLoS Med. 2013;10:e1001526.
12.
HealyD. Let them Eat Prozac. New York: New York University Press; 2004.
13.
DemyttenaereKDonneauA-FAlbertAAnsseauMConstantEvan HeeringenK. What is important in being cured from depression? Discordance between physicians and patients (1). J Affect Disord. 2015;174:390–6.
14.
ZimmermanMMartinezJAAttiullahNFriedmanMTobaCBoerescuDA Why do some depressed outpatients who are in remission according to the Hamilton depression rating scale not consider themselves to be in remission? J Clin Psychiatry. 2012;73:790–5.
15.
ZimmermanMMcGlincheyJBPosternakMAFriedmanMAttiullahNBoerescuD. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163:148–50.
16.
PasquiniMTarsitaniLPiacentinoDMorettiGRoscioliCLeoneCPatients’ expectations for antidepressant treatment outcome. Psychother Psychosom. 2009;78:390–1.
17.
BridgesKHuxleyPMohamadHOliverJ. Quality of Life and Mental Health Services. London: Routledge; 2005.
18.
BrazierJConnellJPapaioannouDMukuriaCMulhernBPeasgoodTA systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18:1–122.
19.
BrazierJ. Measuring and Valuing Health Benefits for Economic Evaluation. Oxford University Press; 2007.
20.
FitzpatrickRDaveyCBuxtonMJonesD. Evaluating patient-based outcome measures for use in clinical trials: A review. Health Technol Assess. 1998;2:1–74.
21.
AraRBrazierJ. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11:1131–43.
22.
GøtzschePCJørgensenAW. Opening up data at the European Medicines Agency. BMJ. 2011;342:d2686.
23.
Court of Justice of the European Union. PRESS RELEASE No 6/20, Luxembourg, 22 January 2020. Judgments in Case C-175/18PPTC Therapeutics International Ltd v European Medicines Agency (EMA), and C-178/18P MSD Animal Health Innovation and Intervet International v European Medicines Agency (EMA). Available from: https://curia.europa.eu/jcms/upload/docs/application/pdf/2020-01/cp200006en.pdf (accessed 10 Sept 2020).
GoldsteinDJMallinckrodtCLuYDemitrackMA. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psych. 2002;63:225–31.
26.
NemeroffCBSchatzbergAFGoldsteinDJDetkeMJMallinckrodtCLuYDuloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002;36:106–32.
27.
YalcinIViktrupL. Comparison of physician and patient assessments of incontinence severity and improvement. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1291–5.
28.
ViktrupLYalcinI. Duloxetine treatment of stress urinary incontinence in women: Effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. Eur J Obstet Gynecol Reprod Biol. 2007;133:105–13.
29.
HurleyDTurnerCBayganiSYalcinIViktrupL. Duloxetine for the treatment of SUI in women: An integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol. 2006;125:120–8.
30.
ArnoldLMLuYCroffordLJWohlreichMDetkeMJIyengarSA double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–84.
31.
ArnoldLMPritchettYLD’SouzaDNKajdaszDKIyengarSWernickeJF. Duloxetine for the treatment of fibromyalgia in women: Pooled results from two randomized, placebo-controlled clinical trials. J Womens Health. 2007;16:1145–56.
32.
GoldsteinDJLuYDetkeMJLeeTCIyengarS. Duloxetine versus placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–18.
33.
WernickeJFRaskinJRosenAPritchettYLD’SouzaDNIyengarSDuloxetine in the long-term management of diabetic peripheral neuropathic pain: An open label, 52-week extension of a randomized controlled clinical trial. Curr Ther Clin Exp. 2006;67:283–304.
34.
YuenEGueorguievaIAaronsL. Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models. Pharm Res. 2014, [epub ahead of print]. doi:10.1007/s11095-014-1380-9.
35.
WasanADOssannaMJRaskinJWernickeJFRobinsonMJHallJASafety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr Drug Safety. 2009;4:22–9.
36.
FishbainDAHallJARisserRCGonzalesJS. Does pain cause the perception of fatigue in patients with chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine. Pain Pract. 2009;9:354–62.
37.
GuastellaVMickG. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. Diabetes Metab. 2009;35:12–9.
38.
WernickeJFPrakashAKajdaszDKHoustonJ. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications. 2009;23:349–59.
39.
FishbainDAHallJMeyersALGonzalesJMallinckrodtC. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine. J Pain Symptom Manage. 2008;36:639–47.
40.
ArmstrongDGChappellASLeTKKajdaszDKBackonjaMD’SouzaDNDuloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes. Pain Med. 2007;8:410–8.
41.
PritchettYLMcCarbergBHWatkinJGRobinsonMJ. Duloxetine for the management of diabetic peripheral neuropathic pain: Response profile. Pain Med. 2007;8:397–409.
42.
FishbainDBermanKKajdaszDK. Duloxetine for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep. 2006;10:199–204.
43.
HallJAWangFOakesTMUtterbackBGCrucittiAAcharyaN. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: Analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf. 2010;9:525–37.
44.
CardozoLDrutzHPBayganiSKBumpRC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol. 2004;104:511–9.
45.
BerardRFongRCarpenterDThomasonCWilkinsonC. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolescent Psychopharmacol. 2006;16:59–75.
46.
SteinDJVersianiMHairTKumarR. Efficacy of paroxetine for relapse prevention in social anxiety disorder: A-24 week study. Arch Gen Psych. 2002;59:1111–8.
47.
TuckerPZaninelliRYehudaRRuggieroLDillinghamKPittsCD. Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:860–8.
48.
MarshallRDBeebeKLOldhamMZaninelliR. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo- controlled study. Am J Psychiat. 2001;158:1982–8.
49.
SteinDJDavidsonJSeedatSBeebeK. Paroxetine in the treatment of post-traumatic stress disorder: Pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003;4:1829–38.
50.
StocchiFNorderaGJokinenRHLepolaUMHewettKBrysonHEfficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64:250–8.
51.
MaundETendalBHróbjartssonAJørgensenKJLundhASchrollJBenefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: Comparison of clinical study reports, trial registries, and publications. BMJ. 2014;348:g3510.
52.
NortonPAZinnerNRYalcinIBumpRC. Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002;187:40–8.
53.
BumpRCNortonPAZinnerNRYalcinI. Duloxetine Urinary Incontinence Study Group. Mixed urinary incontinence symptoms: Urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol. 2003;102:76–83.
54.
KajdaszDKIyengarSDesaiahDBackonjaMMFarrarJTFishbainDADuloxetine for the management of diabetic peripheral neuropathic pain: Evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29 Suppl:2536–46.
55.
WuEQBirnbaumHGMarevaMNLeTKRobinsonRLRosenACost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain. 2006;7:399–407.
56.
van AmeringenMALaneRMWalkerJRBowenRCChokkaPRGoldnerEMSertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:275–81.
57.
HuntSMMcKennaSP. The QLDS: A scale for the measurement of quality of life in depression. Health Policy. 1992;22:307–19.
58.
EndicottJNeeJHarrisonWBlumenthalR. Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull. 1993;29:321–6.
59.
ParkinDRiceNDevlinN , Statistical analysis of EQ-5D profiles: Does the use of value sets bias inference? Med Decis Making. 2010;30:556–65.
60.
HamerRMSimpsonPM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry. 2009;166:639–41.
61.
JørgensenAWLundstrømLHWetterslevJAstrupAGøtzschePC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. PLoS One. 2014;9:e111964.
62.
WoolleySBCardoniAAGoetheJW. Last-Observation-Carried-Forward imputation method in clinical efficacy trials: Review of 352 antidepressant studies. Pharmacotherapy. 2009;29:1408–16.
63.
SharmaTGuskiLSFreundNMengDMGøtzschePC. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. Int J Risk Saf Med. 2019;30:217–32.
64.
RasmussenKBeroLRedbergRGøtzschePCLundhA. Collaboration between academics and industry in clinical trials: Cross sectional study of publications and survey of lead academic authors. BMJ. 2018;363:k3654.
